Brought to you by 
AstraZeneca buys diabetes business from BMS for $2.7bn up front, plus earn-outs
11 May 2016
Executive Summary
After six years of working together and equally sharing global profits from a large joint portfolio, Bristol-Myers Squibb Co. decided to sell its diabetes business to AstraZeneca PLC for $2.7bn in cash. The transaction also includes up to $1.4bn in potential regulatory-, launch- and sales-based earn-outs, plus $225mm in asset transfer payments (related to BMS's Mt. Vernon, Indiana manufacturing facility and Chinese business) and royalties on sales through 2025.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Divestiture/Spin-Out
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AstraZeneca buys diabetes business from BMS for $2.7bn up front, plus earn-outs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice